NCT00875433View on ClinicalTrials.gov

Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

April 30, 2011

Conditions
Neoplasms
Interventions
DRUG

BIBW 2992

patients to receive continuous oral daily dosing of BIBW 2992

Trial Locations (4)

Unknown

1200.24.4403 Boehringer Ingelheim Investigational Site, Guildford

1200.24.4402 Boehringer Ingelheim Investigational Site, London

1200.24.4404 Boehringer Ingelheim Investigational Site, London

1200.24.4401 Boehringer Ingelheim Investigational Site, Sutton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY